order
assess
immunotherapeut
potenti
canin
viscer
leishmaniasi
leishmun
vaccin
formul
increas
adjuv
concentr
mg
saponin
rather
mg
mongrel
dog
infect
leishmania
l
chagasi
enrichedleishmun
vaccin
inject
month
infect
anim
seroposit
symptomat
control
group
inject
salin
solut
leishmun
treat
dog
show
significantli
higher
level
antifml
igg
antibodi
anova
p
higher
stabl
decreas
respons
point
cell
mediat
respons
vaccin
follow
effect
led
posit
delay
type
hypersensit
reaction
leishmania
lysat
vaccin
dog
control
decreas
averag
leishmaniaspecif
lymphocyt
salin
control
fell
outsid
confid
interv
vaccine
increas
averag
clinic
score
salin
control
fall
outsid
confid
interv
leishmun
immunotherapytr
dog
dog
receiv
vaccin
cluster
show
lower
clinic
score
normal
count
wherea
untreat
dog
show
diminish
higher
clinic
score
increas
clinic
sign
salin
treat
group
correl
increas
antifml
antibodi
p
parasitolog
evid
p
decreas
leishmaniaspecif
lymphocyt
proport
p
result
confirm
immunotherapeut
potenti
enrichedleishmun
vaccin
vaccin
reduc
clinic
symptom
evid
parasit
modul
outcom
infect
dog
potenti
infectios
phlebotomin
enrichedleishmun
vaccin
subject
safeti
analysi
found
well
toler
safe
leishmania
l
chagasi
leishmania
l
infantum
etholog
agent
human
kalaazar
america
mediterranean
basin
middl
east
asian
countri
kalaazar
sever
frequent
lethal
diseas
untreat
onset
symptom
region
result
canid
zoonos
parasit
found
expos
skin
fox
wild
canid
dog
transmit
human
sand
fli
bite
zoonot
viscer
leishmaniasi
zvl
reemerg
canid
zoonos
epidemiolog
control
involv
elimin
seroposit
infect
dog
insecticid
treatment
within
domest
peridomest
habit
systemat
treatment
human
case
brazil
one
four
countri
respons
total
human
case
world
tool
epidemiolog
control
kill
seroposit
dog
wide
practis
brazil
china
unaccept
europ
canin
surveil
program
labori
expens
requir
continu
vigil
sensit
serolog
diagnost
method
effect
furthermor
sinc
mani
seroposit
infect
dog
asymptomat
owner
complianc
complic
even
though
infect
asymptomat
dog
sand
fli
alreadi
proven
sacrific
seroposit
anim
epidemiolog
control
still
perform
chemotherapi
infect
dog
use
pentaval
antimoni
mostli
unsuccess
accus
exacerb
diseas
report
increas
surviv
rate
possibl
cure
potenti
howev
stimul
research
dog
therapi
zvl
treatment
infect
dog
usual
practis
europ
adopt
brazil
dog
therapi
still
recommend
sinc
human
canin
treatment
perform
drug
fact
rais
risk
rise
number
drugresist
parasit
treatment
promot
clinic
cure
better
qualiti
life
amastigot
remain
present
mean
dog
might
remain
infecti
sand
fli
even
sever
month
treatment
presenc
latent
infect
dog
typic
import
maintain
longterm
presenc
parasit
endem
region
develop
protect
vaccin
canin
viscer
leishmaniasi
recommend
possibl
tool
effect
erad
diseas
reduc
offer
parasit
sand
fli
vector
consequ
number
human
kalaazar
case
data
effect
prophylact
vaccin
human
kalaazar
still
preliminari
partial
protect
canin
viscer
leishmaniasi
report
kennel
studi
leishmun
vaccin
prophylact
formul
canin
viscer
leishmaniasi
recent
licens
brazil
vaccin
dog
first
regist
vaccin
leishmaniasi
compos
fml
fucosemannos
ligand
antigen
leishmania
donovani
riedel
de
haen
saponin
contain
deacyl
saponin
quillaja
saponaria
main
adjuv
compon
formul
obtain
laboratori
condit
prove
safe
protect
highli
immunogen
hamster
mice
dog
brazilian
area
endem
human
dog
viscer
leishmaniasi
recent
phase
iii
trial
efficaci
use
fmlsaponin
dog
induc
protect
dog
expos
diseas
vaccin
efficaci
respect
protect
induc
fmlquila
vaccin
last
year
vaccin
time
vaccine
show
higher
seroposit
intraderm
reaction
leishmani
dna
parasit
bone
marrow
punctur
fmlquila
vaccin
induc
signific
longlast
strong
protect
effect
canin
viscer
leishmaniasi
field
hand
dog
receiv
salin
pcr
posit
leishmania
dna
amastigot
bone
marrow
fmlserolog
intraderm
reaction
industri
produc
leishmun
vaccin
recent
demonstr
accept
safeti
immunogen
characterist
highli
expos
endem
area
healthi
dog
vaccin
leishmun
remain
free
parasit
noninfecti
sand
fli
parasitolog
criteria
month
vaccin
sand
fli
fed
vivo
serum
dog
vaccin
leishmun
month
show
reduc
infect
comparison
sand
fli
fed
preimmun
dog
sera
indic
leishmun
transmiss
block
vaccin
tbv
potenti
import
impact
interrupt
epidemiolog
cycl
viscer
leishmaniasi
consid
rel
failur
chemotherapi
canin
viscer
leishmaniasi
neg
impact
epidemiolog
control
diseas
possibl
use
protect
vaccin
immunotherapi
alreadi
infect
dog
highli
encourag
would
broader
commun
accept
control
effort
base
instead
kill
infect
dog
impress
protect
achiev
fmlvaccin
field
phase
iii
assay
leishmun
date
rais
perspect
use
immunotherapeut
canin
trial
hypothesi
support
recent
result
show
fmlsaponin
vaccin
among
other
shown
immunotherapeut
mice
seroposit
asymptomat
dog
brazilian
endem
area
differ
vaccin
previous
use
healthi
dog
infect
dog
receiv
fmlsaponin
vaccin
increas
adjuv
concentr
mg
saponin
schedul
three
dose
month
interv
annual
booster
treat
dog
show
stabl
antifml
level
increas
level
posit
dth
respons
whole
experi
twentytwo
month
complet
vaccin
death
due
viscer
leishmaniasi
record
dog
still
asymptomat
healthi
parasit
free
dog
remain
healthi
five
year
initi
vaccin
hand
dog
kalaazar
death
record
control
group
receiv
treatment
period
dog
fmlseroposit
asymptomat
begin
studi
result
indic
fmlvaccin
effect
immunotherapi
viscer
leishmaniasi
asymptomat
infect
dog
normal
proport
lymphocyt
detect
pbmc
fac
analysi
dog
submit
immunotherapi
suggest
non
infecti
condit
expect
treat
anim
show
significantli
increas
percentag
lymphocyt
typic
quillaja
saponin
quila
vaccin
treatment
investig
report
potenti
use
industri
formul
fmlsaponin
vaccin
leishmun
increas
concentr
saponin
mg
immunotherapeut
effect
investig
infect
seroposit
symptomat
dog
experiment
canin
viscer
leishmaniasi
twentyfour
mongrel
dog
old
six
differ
litter
vaccin
rabi
raivac
canin
distemp
type
adenoviru
coronaviru
parainfluenza
parvoviru
leptospira
duramun
fort
dodg
anim
health
ia
usa
treat
antihelminth
drug
drontal
plu
bayer
dog
healthi
seroneg
leishmania
antibodi
fmlelisa
assay
experiment
infect
iv
rout
amastigot
obtain
leishmania
l
chagasi
infect
hamster
spleen
anim
becam
seroposit
fml
antigen
month
random
one
six
litter
perform
draft
order
divid
two
balanc
group
one
half
litter
receiv
salin
control
second
half
vaccin
salin
control
compos
dog
famili
famili
b
famili
c
famili
dog
famili
e
vaccin
group
includ
dog
famili
famili
b
famili
c
famili
dog
famili
e
control
group
treat
steril
nacl
salin
solut
immunotherapi
group
receiv
leishmun
enrich
vaccin
contain
mg
fml
industri
antigen
fort
dodg
anim
health
mg
riedel
de
haen
saponin
vaccin
given
three
dose
inject
sc
rout
back
day
interv
essenti
month
formul
differ
adjuv
concentr
leishmun
vaccin
formul
contain
mg
saponin
industri
regist
brazil
prophylact
vaccin
canin
viscer
leishmaniasi
patent
inpi
number
feder
univers
rio
de
janeiro
brazil
dog
monitor
follow
paramet
antifml
igg
antibodi
level
delay
type
hypersensit
dth
ft
promastigot
lysat
antigen
pbmc
lymphocyt
phenotyp
clinic
sign
anim
clinic
evalu
monthli
basi
alopecia
onycogryphosi
cachexia
anorexia
isol
apathi
skin
lesion
poplit
cervic
lymph
node
enlarg
loss
weight
score
system
clinic
sign
infect
base
seri
factor
includ
diamet
small
cm
medium
cm
larg
cm
lymph
node
weight
loss
also
consid
mild
mw
kg
sever
sw
kg
detect
alopecia
onycogryphosi
cachexia
anorexia
isol
apathi
skin
lesion
attribut
valu
score
normal
undetect
small
medium
enlarg
lymph
node
respect
also
score
attribut
mild
loss
weight
sever
loss
weight
evalu
presenc
parasit
perform
vitro
cultur
blood
bone
marrow
dog
sampl
biphas
cultur
media
nnn
blood
supplement
agar
solid
phase
fetal
calf
serum
supplement
brain
heart
infus
mgml
hemin
mgml
folic
acid
liquid
phase
microscop
monitor
three
cultur
passag
day
vivo
cultur
dog
blood
bone
marrow
sampl
cb
hamster
inocul
intracardiac
rout
case
presenc
parasit
assay
microscopi
analysi
liver
spleen
giemsa
stain
smear
day
surviv
analysi
furthermor
pcr
analysi
leishmania
dna
bone
marrow
sampl
month
perform
giemsa
stain
dog
poplit
lymph
node
smear
obtain
fine
needl
biopsi
month
also
microscop
evalu
fifteen
month
infect
anim
sacrif
anaesthesia
ml
euthanasia
intervet
sp
brazil
via
iv
presenc
leishmania
amastigot
assess
giemsa
stain
touch
biopsi
spleen
liver
lymph
node
smear
anim
includ
investig
treat
follow
guidelin
anim
experiment
usa
nation
institut
health
experi
done
accord
institut
guidelin
order
minim
anim
suffer
three
vaccin
dose
inject
subcutan
neck
veterinarian
record
presenc
absenc
potenti
vaccin
advers
event
local
pain
local
swell
anorexia
apathi
vomit
diarrhoea
reaction
observ
day
inject
observ
pain
reaction
touch
inject
site
record
pain
reaction
dog
look
inject
site
skin
contract
observ
dog
whine
tri
bite
hand
observ
local
swell
inject
site
detect
palpat
rang
cm
diamet
anim
dog
ate
less
usual
andor
reject
food
anorexia
record
dog
stand
approach
observ
apathi
record
dog
sera
evalu
monthli
presenc
total
antileishmania
donovani
antibodi
fmlelisa
assay
use
fml
antigen
gwell
solubil
carbon
buffer
ph
coat
flatbottom
plate
corn
cat
number
highli
absorb
total
antibodi
detect
use
peroxidaselabel
proteina
kirkegaard
perri
laboratori
gaithersburg
maryland
dilut
block
buffer
cutoff
fmlelisa
assay
determin
youden
test
calcul
ab
mean
averag
absorb
valu
normal
healthi
serum
plu
standard
deviat
result
express
mean
valu
triplic
absorb
valu
compar
use
dilut
individu
serum
sampl
furthermor
goat
antidog
heavi
chain
specif
bethyl
laboratori
inc
montgomeri
tx
usa
conjug
horseradishperoxidas
use
igg
subtyp
determin
pool
total
sera
time
determin
inject
dog
intraderm
month
infect
dog
inject
inner
side
right
hind
leg
ml
l
donovani
freezethaw
antigen
contain
g
protein
nacl
steril
salin
solut
stationari
phase
promastigotesml
left
hind
leg
receiv
ml
salin
measur
increas
intraderm
reaction
perform
h
antigen
inject
indur
area
mark
time
valu
salin
control
subtract
reaction
due
leishmania
antigen
reaction
show
diamet
mm
consid
posit
twelv
month
infect
pbmc
count
dog
obtain
ml
cephal
vein
blood
collect
heparintub
exvivo
analysi
l
blood
incub
min
room
temperatur
l
one
follow
monoclon
antibodi
dilut
fac
dil
solut
fc
supplement
pb
buffer
thirti
microlit
antirat
serum
serotec
oxford
uk
pb
use
neg
control
period
ml
pbsw
pb
buffer
bovin
serum
albumin
sodium
azid
ad
tube
mixtur
homogenis
centrifug
rpm
room
temperatur
min
supernat
aspir
pellet
homogenis
ad
l
antirat
fitc
conjug
serotec
uk
except
pb
cell
control
time
l
fitclabel
mous
monoclon
antibodi
immunotech
co
marseil
franc
use
direct
immunofluoresc
procedur
suspens
homogenis
incub
min
room
temperatur
dark
treat
ml
dilut
lysi
solut
vortex
homogen
becton
dickinson
usa
mixtur
incub
min
room
temperatur
dark
centrifug
rpm
min
supernat
discard
pelletcontain
tube
invert
absorb
paper
procedur
repeat
twice
addit
ml
pb
pellet
homogenis
care
final
fix
l
formaldehydepb
altern
pbmc
leishmaniaspecif
lymphocyt
analys
vitro
prolifer
leishmania
antigen
one
millilit
cephal
vein
blood
dilut
ml
rpmi
medium
sigma
co
cushion
ml
histopaqu
cat
number
sigma
co
centrifug
rpm
min
room
temperatur
fraction
contain
pbmc
aspir
wash
three
time
rpmi
rpm
min
c
cell
count
haemocytomet
twentyfour
well
plate
nunc
nunclon
denmark
plat
cell
fc
supplement
rpmi
incub
five
day
c
co
presenc
lysat
stationari
phase
promastigot
leishmania
l
chagasi
period
cell
harvest
wash
twice
pb
rpm
min
pellet
label
l
primari
monoclon
antibodi
describ
wash
twice
incub
conjug
wash
twice
final
fix
formaldehydepb
ten
thousand
cell
analyz
flow
cytometri
becton
dickinson
facscalibur
apparatu
analyz
use
winmdi
window
multipl
document
interfac
flow
cytometri
applic
version
softwar
one
millilit
peripher
blood
cephal
vein
bone
marrow
sternum
aspir
collect
edta
tube
store
c
dna
extract
ml
sampl
thaw
wash
ml
te
buffer
mm
tri
mm
edta
centrifug
g
treat
lysi
buffer
sodium
dodecyl
sulphatesd
sodium
acet
gml
proteinas
k
c
one
hour
lysat
treat
l
phenolchloroformisoamil
alcohol
dna
precipit
ethanol
dri
ressuspend
l
te
buffer
pcr
analysi
perform
use
primer
gtg
ggg
gag
ggg
cgt
tct
att
tta
cac
caa
ccc
cca
gtt
amplifi
conserv
region
kinetoplast
minicircl
dna
leishmania
genu
previous
describ
rodger
et
al
pcr
assay
abl
detect
minimum
leishmania
parasit
amplifi
product
analyz
agaros
gel
contain
gml
ethidium
bromid
sigma
co
dna
ladder
invitrogen
tm
use
marker
gel
visual
uv
light
transillumin
mean
compar
anova
analysi
simpl
factori
test
oneway
anova
tukey
honestli
signific
differ
method
use
spss
window
test
signific
differ
group
also
use
confid
interv
averag
proport
compar
test
correl
coeffici
analysi
determin
pearson
bivari
twotail
test
signific
spss
order
assess
immunotherapeut
potenti
leishmun
vaccin
canin
viscer
leishmaniasi
formul
increas
adjuv
concentr
mg
saponin
mongrel
dog
infect
amastigot
l
l
chagasi
obtain
hamster
spleen
anim
monitor
monthli
antifml
igg
antibodi
fig
b
month
infect
antibodi
detect
month
day
infect
anim
start
give
posit
result
fmlelisa
assay
cutoff
ab
month
first
clinic
sign
note
point
enrichedleishmun
vaccin
inject
immunotherapi
group
month
control
group
receiv
salin
start
month
soon
first
vaccin
dose
expect
saponincontain
vaccin
rapid
increas
igg
antifml
antibodi
observ
vaccine
control
dog
show
lower
stabl
titter
fig
anova
analysi
reveal
signific
differ
time
p
treatment
p
differ
start
month
studentnewmankeul
methodspss
window
four
control
dog
number
turn
seroneg
month
indic
control
spontan
resolut
infect
determin
isotyp
antibodi
produc
fml
antigen
group
dog
fig
show
tcell
respons
tcell
respons
absorb
regard
antifml
antibodi
anim
vaccin
enrichedleishmun
vaccin
induc
high
level
specif
igg
antibodi
fig
also
show
increas
respons
salin
control
group
show
antibodi
level
time
infect
month
immunotherapi
treatment
induc
higher
stabl
respons
vaccin
type
immun
respons
respons
decreas
untreat
control
progress
infect
hand
antibodi
diminish
vaccin
show
mild
trend
increas
untreat
infect
anim
immun
respons
fig
cellular
immun
respons
first
assay
analysi
dth
respons
l
l
donovani
lysat
individu
dth
reaction
monitor
month
summar
fig
immunotherapi
treatment
lead
protect
effect
show
posit
reaction
vaccin
dog
untreat
control
month
complet
vaccin
vaccine
control
show
posit
dth
respons
mm
diamet
fig
also
month
reaction
posit
receiv
vaccin
control
fig
neither
differ
percentag
posit
reaction
squar
test
size
skin
swell
signific
anova
p
differ
treatment
p
differ
time
probabl
heterogen
reaction
mm
control
dog
spontan
lost
antibodi
respons
fig
show
expect
high
idr
valu
mm
confirm
resist
condit
infect
natur
protect
cellular
immun
respons
also
evalu
mean
rel
proport
pbmc
lymphocyt
subset
month
infect
cell
immunosuppress
reduct
lymphocyt
popul
expect
occur
sever
kalaazar
posit
relat
infect
statu
dog
insect
vector
tabl
increas
clinic
sign
correl
increas
antifml
antibodi
salin
treat
group
p
pearson
two
tail
correl
coeffici
indic
experiment
infect
reproduc
develop
natur
diseas
dog
asymptomat
begin
assay
six
month
infect
vaccin
treatment
begun
tabl
increas
number
symptom
note
vaccine
untreat
control
throughout
experi
differ
number
clinic
sign
highli
signific
treatment
anova
p
time
anova
p
number
clinic
sign
higher
salin
control
differ
number
sign
treatment
start
month
tabl
vaccin
complet
p
studentnewmankeul
test
tukey
honestli
signific
differ
spss
window
also
littl
differ
seen
total
score
treat
untreat
anim
soon
vaccin
month
stronger
differ
notic
month
score
untreat
vaccin
dog
respect
also
describ
evolut
clinic
sign
viscer
leishmaniasi
use
score
quantifi
number
sign
discrimin
slight
sever
symptom
tabl
three
level
lymph
node
enlarg
discrimin
detect
small
sl
cm
medium
ml
cm
larg
lymph
node
cm
loss
weight
also
consid
level
mild
loss
mw
rang
kg
level
anim
clinic
evalu
monthli
alopecia
onycogryphosi
skin
lesion
oedema
oe
poplit
cervic
lymph
node
enlarg
loss
weight
three
level
lymph
node
enlarg
discrimin
detect
small
sl
cm
medium
ml
cm
larg
lymph
node
cm
loss
weight
also
classifi
mild
weight
loss
mw
rang
kg
sever
weight
loss
sw
rang
kg
detect
alopecia
onycogryphosi
skin
lesion
oedema
consid
valu
sever
loss
sw
rang
kg
detect
alopecia
onycogryphosi
skin
lesion
oedema
oe
consid
valu
death
sever
kalaazar
case
detect
studi
period
dog
die
month
end
experi
due
accid
appar
relat
diseas
averag
score
total
clinic
sign
express
number
sever
viscer
leishmaniasi
symptom
salin
control
fall
outsid
confid
interv
leishmun
immunotherapytr
dog
confirm
protect
induc
leishmun
immunotherapi
treatment
reduc
number
sever
symptom
number
clinic
sign
correl
declin
leishmaniaspecif
lymphocyt
proport
p
pearson
two
tail
correl
coeffici
point
onset
kalaazar
immunosuppres
fig
hand
untreat
control
number
spontan
lost
antibodi
respons
fig
sustain
normal
count
show
strong
idr
reaction
display
lowest
score
clinic
sign
tabl
ili
e
despit
common
genet
background
highli
protect
fig
tabl
summar
result
parasit
evid
dog
month
infect
result
parasit
detect
liver
spleen
lymph
node
obtain
autopsi
month
posit
result
seen
month
vitro
cultur
analysi
blood
bone
marrow
sampl
result
shown
hand
vivo
parasit
amplif
blood
sign
total
bone
marrow
lymph
node
sampl
hamster
month
bone
marrow
pcr
analysi
month
show
higher
sensit
tabl
record
posit
hamster
infect
dog
sampl
day
either
die
viscer
leishmaniasi
parasit
spleen
liver
take
account
proport
posit
result
among
total
evalu
salin
treat
group
show
higher
percent
parasit
evid
leishmun
treat
group
tabl
indic
salin
treat
anim
diseas
progress
wherea
vaccin
anim
control
parasitaemia
probabl
potenti
infecti
insect
differ
howev
statist
signific
note
dog
salin
control
dog
vaccin
group
show
parasit
evid
belong
famili
litter
suggest
possibl
genet
background
resist
anim
signific
posit
correl
found
evolut
number
symptom
number
parasitolog
evid
time
p
start
month
infect
soon
complet
vaccin
confirm
protect
potenti
enrichedleishmun
vaccin
reduc
clinic
symptom
parasit
evid
infecti
vaccin
dog
modul
outcom
infect
safeti
reactogen
mg
saponinleishmun
vaccin
also
assess
incid
advers
effect
dog
vaccin
mgleishmun
vaccin
quantifi
percentag
dog
show
sign
pain
local
swell
apathi
anorexia
diarrhoea
vomit
tabl
record
one
inject
vaccin
number
dog
show
pain
significantli
increas
dose
p
anova
pain
vaccin
dose
last
h
p
local
swell
commonli
notic
advers
effect
although
number
reactiv
dog
appar
increas
first
dose
tabl
signific
differ
dose
note
also
anim
swell
reaction
transient
declin
first
h
dose
complet
disappear
fourth
day
inject
tabl
apathi
reaction
significantli
decreas
p
first
h
hour
dose
p
tukey
honestli
signific
differ
method
spss
window
death
anorexia
vomit
diarrhoea
allergi
anaphylact
effect
regist
indic
advers
effect
mild
vaccin
toler
result
evolut
antifml
igg
antibodi
idr
l
l
donovani
lysat
leishmaniaspecif
lymphocyt
count
blood
vitro
parasit
dna
evid
clinic
sign
point
posit
immunotherapeut
potenti
mg
saponinleishmun
vaccin
develop
canin
viscer
leishmaniasi
potenti
effect
dog
infecti
phlebotomin
toxic
analysi
reveal
vaccin
safe
accept
reactogen
phase
iia
trial
design
check
vaccineinduc
protect
experiment
challeng
although
need
order
standard
vaccin
dosag
rout
schedul
previou
field
test
main
limit
question
repres
artifici
challeng
inde
result
obtain
challeng
use
laboratoryadapt
parasit
strain
challeng
differ
induc
parasit
natur
effect
particularli
strike
case
typic
insectborn
diseas
viscer
leishmaniasi
although
leishmania
l
chagasi
strain
use
work
isol
human
kalaazar
case
previous
use
challeng
two
kennel
studi
promastigot
induc
death
sever
case
viscer
leishmaniasi
among
infect
control
inde
use
high
inoculum
amastigot
consid
two
million
time
higher
deliv
natur
three
untreat
control
dog
three
vaccin
anim
dog
develop
mild
infect
heterogen
outcom
canin
viscer
leishmaniasi
infect
spontan
remiss
well
describ
literatur
find
dog
asymptomat
spontan
cure
expect
occur
group
interestingli
dog
belong
famili
litter
suggest
genet
base
resist
infect
recent
prove
dog
low
infect
leishmania
strain
awar
fact
purpos
random
srd
anim
accord
famili
origin
distribut
half
litter
salin
control
half
vaccin
group
determin
dog
compos
group
done
draft
natur
resist
imped
howev
signific
increas
symptomatolog
decreas
leishmaniaspecif
count
salin
control
whose
averag
fell
outsid
vaccin
dog
disclos
protect
effect
immunotherapi
treatment
ramiro
et
al
justifi
use
higher
inoculum
assur
lack
infect
protect
anim
due
immun
respons
achiev
vaccin
natur
resist
diseas
absenc
sever
clinic
sign
death
investig
work
ramiro
et
al
presenc
anim
resist
infect
prove
howev
high
inoculum
guarante
suscept
probabl
associ
natur
inocul
phlebotomin
bite
variat
dog
genet
background
associ
describ
gene
andor
mhc
classii
genotyp
significantli
associ
level
antileishmania
igg
parasit
statu
assess
pcr
case
mongrel
dog
particip
present
phase
iia
trial
inde
repres
suscept
heterogen
dog
popul
diseas
found
larger
natur
popul
studi
immunotherapeut
effect
antileishmania
vaccin
mice
dog
preliminari
develop
immunotherapeut
tool
viscer
leishmaniasi
particularli
import
brazil
control
campaign
human
kalaazar
base
remov
sacrific
infect
dog
chemotherapi
recommend
complet
effici
maintain
parasit
reservoir
potenti
effect
fml
fucosemannos
ligand
vaccin
immunotherapi
canin
viscer
leishmaniasi
first
demonstr
l
l
chagasi
natur
infect
dog
seroposit
fml
complet
asymptomat
begin
vaccin
untreat
control
die
vaccine
remain
asymptomat
healthi
normal
lymphocyt
proport
month
vaccin
dog
also
receiv
fmlsaponin
prepar
mg
adjuv
remain
healthi
asymptomat
five
year
unpublish
result
use
increas
saponin
concentr
base
previou
effect
result
immunotherapi
murin
model
differ
previou
result
experiment
infect
l
l
donovani
natur
infect
l
l
chagasi
day
antileishmania
antibodi
investig
becam
evid
day
literatur
estim
seroconvers
natur
occur
averag
day
infect
take
day
dog
becom
symptomat
infecti
insect
vector
day
result
indic
lower
virul
l
l
chagasi
strain
show
delay
seroconvers
signific
correl
howev
found
untreat
dog
increas
antifml
antibodi
increas
clinic
sign
correl
increas
number
parasitolog
evid
decreas
leishmaniaspecif
lymphocyt
proport
variabl
highli
associ
infecti
phlebotomin
mean
spite
use
strain
show
delay
seroconvers
dog
infect
simul
natur
infect
field
hand
vaccin
rapid
signific
increas
igg
antifml
antibodi
observ
vaccine
describ
first
immunoprophylact
vaccin
expect
use
vaccin
compos
quila
saponin
glycoprotein
antigen
higher
antifml
respons
detect
dog
treat
leishmun
togeth
reduct
antibodi
indic
induct
protectivecur
respons
respons
induc
leishmun
similar
achiev
natur
infect
dog
immunotherapi
fmlsaponin
vaccin
seem
stronger
report
ramiro
et
al
dog
vaccin
lack
formul
show
higher
ratio
day
infect
present
studi
maxim
predomin
sustain
month
month
signific
immunolog
respons
clinic
protect
demonstr
investig
signific
posit
correl
found
evolut
number
symptom
number
parasitolog
evid
time
neg
correl
found
increas
clinic
sign
decreas
popul
disclos
cur
potenti
saponin
enrichedleishmun
vaccin
although
clinic
cure
complet
vaccin
dog
accumul
score
much
higher
untreat
treat
anim
inde
score
untreat
anim
increas
month
low
stabl
vaccin
month
suggest
protect
effect
last
throughout
studi
period
cellular
immun
respons
evalu
dth
respons
lymphocytespecif
prolifer
leishmania
antigen
salin
control
show
signific
decreas
leishmanialymphocyt
specif
popul
expect
kalaazar
immunosupress
increas
intraderm
respons
sustain
leishmanialymphocyt
popul
achiev
vaccine
reveal
mediat
immun
respons
differ
previou
result
although
expect
enhanc
immun
parasit
protozoa
anim
treat
quillaja
saponaria
saponin
adjuv
signific
increas
popul
observ
leishmun
vaccin
previou
work
dog
prophylact
vaccin
leishmun
mg
saponin
show
absenc
parasit
correl
neg
reaction
lymph
node
pcr
skin
immunohistochemistri
blood
pcr
analysi
absenc
symptom
present
investig
signific
reduct
number
clinic
sign
correl
decreas
parasitolog
sign
sustain
normal
proport
increas
level
antifml
igg
antibodi
confirm
immunotherapeut
potenti
formul
canin
viscer
leishmaniasi
immunoprophylact
immunotherapeut
vaccin
result
suggest
reduc
infect
vaccin
dog
similar
result
obtain
first
immunotherapi
enrichedleishmun
vaccin
asymptomat
natur
infect
dog
brazilian
endem
area
remain
healthi
five
year
begin
vaccin
treatment
hand
work
increas
symptomatolog
salin
control
correl
increas
igg
antibodi
parasit
evid
decreas
leishmaniaspecif
lymphocyt
popul
confirm
recent
literatur
indic
despit
mild
infect
increas
infecti
phlebotomin
leishmun
prophylact
formul
transmiss
block
vaccin
tbv
dog
antibodi
present
sera
even
month
vaccin
led
inhibit
sand
fli
infect
tbv
properti
leishmun
vaccin
might
enhanc
immunotherapeut
formula
use
studi
increas
saponin
concentr
lack
infecti
leishmun
treat
dog
sand
fli
suggest
normal
level
specif
lymphocyt
lower
proport
parasitolog
evid
high
consist
antifml
antibodi
respons
would
lead
declin
interrupt
epidemi
natur
two
studi
literatur
report
kennel
experi
dog
prophylact
vaccin
viscer
leishmaniasi
due
leishmania
l
infantum
ramiro
et
al
use
prime
boost
dna
plasmid
recombin
vaccinia
viru
express
lack
antigen
rvvlack
l
l
infantum
dog
challeng
l
l
infantum
igg
antibodi
clinic
symptom
found
untreat
control
lackdna
lackdna
rvvlack
treat
dog
rvvlack
formul
also
best
decreas
liver
spleen
parasit
burden
enhanc
vitro
lymphocyt
prolifer
lack
antigen
group
howev
produc
coincident
peak
disappear
one
month
infect
statist
signific
result
howev
avail
probabl
due
small
number
anim
rafati
et
al
use
prime
boost
dna
recombin
protein
cistein
proteinas
b
l
l
infantum
combin
montanid
cpg
ten
dog
challeng
l
l
infantum
vaccin
group
show
igg
antibodi
synthesi
stimul
lymphocyt
prolifer
secret
dth
respons
enhanc
control
less
posit
result
cultur
pcr
leishmania
dna
clinic
sign
report
neither
group
probabl
due
low
infect
challeng
promastigot
main
contribut
studi
analysi
immunogen
vaccin
efficaci
immunogen
potenti
detect
formul
expect
use
montanid
cpg
sequenc
know
highli
heterogen
degre
infect
observ
canin
viscer
leishmaniasi
signific
conclus
might
drawn
studi
use
ten
vaccin
dog
two
control
untreat
dog
saponin
adjuv
concentr
therapeut
leishmun
vaccin
doubl
mg
compos
prophylact
formul
mg
toler
effect
previou
immunotherapi
assay
prophylact
leishmun
dose
contain
g
saponin
main
adjuv
activ
compound
therapeut
formula
includ
g
use
g
show
perfect
toler
mice
vaccin
fmlsaponin
vaccin
also
dose
g
consid
toler
recommend
use
human
submit
melanoma
immunotherapi
babesia
cani
vaccin
compos
parasit
antigen
mg
quila
adjuv
contain
g
quillaja
saponaria
saponin
report
vaccin
contain
time
concentr
immunotherap
leishmun
vaccin
led
local
pain
anorexia
listless
swell
spite
result
use
report
sinc
leishmun
prophylact
vaccin
contain
mg
saponin
induc
transient
reaction
local
pain
anorexia
apathi
local
swell
reaction
vomit
diarrhoea
dead
anaphylaxi
occur
two
dog
show
allerg
reaction
facial
oedema
itch
transient
alopecia
inject
site
occur
dog
total
recoveri
need
treatment
mild
advers
event
respons
leishmun
inject
transient
disappear
inject
follow
vaccin
dose
spite
doubl
adjuv
concentr
use
present
work
number
dog
show
pain
apathi
lower
death
anaphylaxi
anorexia
allergi
vomit
diarrhoea
event
detect
indic
reactogen
increas
doserespons
differ
reactogen
mg
vaccin
might
relat
differ
evalu
protocol
mg
formul
evalu
daili
basi
day
inject
dog
owner
immunotherapeut
vaccin
evalu
experiment
kennel
dog
veterinarian
day
dose
also
vaccin
mg
vaccin
differ
site
inject
use
show
subcutan
inject
neck
induc
less
reaction
present
studi
neck
inject
site
might
explain
detect
lower
reactogen
report
studi
advers
effect
mild
mostli
disappear
within
five
day
inject
increas
advers
effect
immunotherapeut
formul
local
swell
mg
vaccin
mg
vaccin
characterist
expect
inflammatori
respons
subsequ
quillaja
saponaria
saponin
inject
spite
mostli
revert
fourth
day
inject
safeti
assay
mg
industri
leishmun
vaccin
first
one
literatur
actual
describ
reactogen
quillaja
saponaria
vaccin
leishmun
dog
vaccin
consid
toler
non
toxic
studi
dog
vaccin
report
inform
note
differ
report
analysi
new
experiment
vaccin
regard
costbenefit
analysi
one
must
keep
mind
treatment
mg
saponin
vaccin
might
worthwhil
therapeut
potenti
spite
undesir
side
effect
especi
given
zoonot
viscer
leishmaniasi
fatal
human
canin
diseas
increas
endem
area
whose
epidemiolog
control
involv
cull
euthanasia
leishmaniainfect
dog
present
investig
analys
effect
adjuvantenrichedleishmun
vaccin
experiment
canin
viscer
leishmaniasi
conclud
significantli
increas
antibodi
respons
increas
intraderm
respons
sustain
leishmanialymphocyt
popul
togeth
decreas
clinic
parasitolog
sign
diseas
achiev
vaccin
confirm
signific
immunotherapeut
potenti
enrichedleishmun
vaccin
immun
respons
potenti
use
control
canin
viscer
leishmaniasi
endem
area
